Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Go back to Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study| (NASDAQ: ENSC) | Delayed: 0.29 -0.01 (3.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.30 | 52 Week High | $ | |||
| Open | $0.29 | 52 Week Low | $ | |||
| Day High | $0.30 | P/E | N/A | |||
| Day Low | $0.28 | EPS | $ | |||
| Volume | 179,526 | |||||
